UBS Group
ADPT icon

UBS Group’s Adaptive Biotechnologies ADPT Stock Holding History

UBS Group’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.76M Buy
268,439
+42,453
+19% +$650K ﹤0.01% 4023
2026
Q1 		$3.14M Sell
225,986
-285,941
-56% -$4.56M ﹤0.01% 4552
2025
Q4 		$8.31M Buy
511,927
+257,947
+102% +$4.21M ﹤0.01% 3486
2025
Q3 		$3.8M Sell
253,980
-201,426
-44% -$2.45M ﹤0.01% 4321
2025
Q2 		$5.31M Buy
455,406
+179,789
+65% +$1.63M ﹤0.01% 3818
2025
Q1 		$2.05M Sell
275,617
-121,641
-31% -$935K ﹤0.01% 4686
2024
Q4 		$2.38M Buy
397,258
+324,107
+443% +$1.79M ﹤0.01% 4565
2024
Q3 		$375K Buy
73,151
+16,520
+29% +$72K ﹤0.01% 5439
2024
Q2 		$205K Sell
56,631
-86,984
-61% -$276K ﹤0.01% 5646
2024
Q1 		$461K Buy
143,615
+11,095
+8% +$42.9K ﹤0.01% 5264
2023
Q4 		$649K Buy
132,520
+42,202
+47% +$193K ﹤0.01% 4872
2023
Q3 		$492K Sell
90,318
-12,023
-12% -$79.5K ﹤0.01% 4663
2023
Q2 		$687K Buy
102,341
+15,483
+18% +$115K ﹤0.01% 4549
2023
Q1 		$767K Buy
86,858
+24,722
+40% +$218K ﹤0.01% 4342
2022
Q4 		$475K Buy
62,136
+35,131
+130% +$273K ﹤0.01% 4758
2022
Q3 		$193K Buy
27,005
+1,725
+7% +$16.2K ﹤0.01% 5109
2022
Q2 		$205K Sell
25,280
-24,372
-49% -$214K ﹤0.01% 4887
2022
Q1 		$690K Buy
49,652
+50
+0.1% +$786 ﹤0.01% 4446
2021
Q4 		$1.39M Sell
49,602
-2,456
-5% -$75.3K ﹤0.01% 4084
2021
Q3 		$1.77M Buy
52,058
+36,761
+240% +$1.33M ﹤0.01% 3673
2021
Q2 		$625K Sell
15,297
-6,684
-30% -$260K ﹤0.01% 4558
2021
Q1 		$885K Sell
21,981
-986
-4% -$53.4K ﹤0.01% 4384
2020
Q4 		$1.36M Sell
22,967
-3,711
-14% -$191K ﹤0.01% 3758
2020
Q3 		$1.3M Buy
26,678
+3,666
+16% +$154K ﹤0.01% 3451
2020
Q2 		$1.11M Sell
23,012
-3,706
-14% -$135K ﹤0.01% 3418
2020
Q1 		$742K Buy
26,718
+16,788
+169% +$468K ﹤0.01% 3619
2019
Q4 		$297K Sell
9,930
-2,211
-18% -$63.5K ﹤0.01% 5301
2019
Q3 		$375K Buy
+12,141
New +$495K ﹤0.01% 4781

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

UBS Group's ADPT Position: Q2 2026 in Review

UBS Group increased its Adaptive Biotechnologies (ADPT) stake by 19% in Q2 2026, buying an estimated $650K and bringing the position to 268,439 shares worth $5.76M. The position accounts for ﹤0.01% of the portfolio, ranked #4023.

UBS Group first reported a position in ADPT in Q3 2019 and has held it in 28 quarters since. The position peaked at $8.31M in Q4 2025. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • UBS Group held 268,439 shares of Adaptive Biotechnologies worth $5.76M as of Q2 2026.
  • UBS Group bought 42,453 Adaptive Biotechnologies shares in Q2 2026, an estimated $650K.
  • Adaptive Biotechnologies made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #4023 holding.
  • UBS Group first reported a position in Adaptive Biotechnologies in Q3 2019 and has held it in 28 quarters since.
  • UBS Group's Adaptive Biotechnologies position peaked at $8.31M in Q4 2025.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.